CNBC September 12, 2024
Key Points
– Noom on Thursday announced it is offering users access to compounded semaglutide as part of a new weight loss product starting at $149.
– The digital health company already offers branded GLP-1s through its platform, but it wanted to give patients access to a cheaper alternative.
– Noom said its new offering also supports patients if they decide they want to taper off the medication.
Digital health company Noom on Thursday announced it will offer a compounded GLP-1 drug as part of a new weight loss product that starts at $149.
The treatment will feature compounded semaglutide, the same active ingredient in Novo Nordisk‘s blockbuster obesity and diabetes drugs Wegovy and Ozempic. Noom has offered weight...
Today's Sponsors
Today's Sponsor